Phase II Trial of Afatinib in Elderly Patients Aged Over 75 Years with EGFR Mutation Positive Non-Small Cell Lung Cancer

被引：1
|
作者：
Ko, R. [1 ]
Oizumi, S. [2 ]
Mizugaki, H. [3 ]
Fujita, Y. [2 ]
Harada, T. [4 ]
Takashina, T. [5 ]
Igawa, S. [6 ]
Watanabe, K. [7 ]
Hotta, T. [8 ]
Minemura, H. [9 ]
Saeki, S. [10 ]
Yagishita, S. [11 ]
Hamada, A. [11 ]
机构：
[1] Juntendo Univ, Grad Sch Med, Resp Med, Tokyo, Japan
[2] Natl Hosp Org Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[3] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[4] Jcho Hokkaido Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan
[5] Iwamizawa Municipal Gen Hosp, Iwamizawa, Japan
[6] Kitasato Univ, Sch Med, Resp Med, Sagamihara, Kanagawa, Japan
[7] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[8] Shimane Univ, Fac Med, Izumo, Shimane, Japan
[9] Fukushima Med Univ, Pulm Med, Fukushima, Japan
[10] Kumamoto Univ, Kumamoto, Japan
[11] Natl Canc Ctr, Res Inst, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Afatinib; Adverse events; Elderly patients;
D O I：
10.1016/j.jtho.2019.08.1187
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.14-36
引用
收藏
页码：S568 / S568
页数：1
相关论文
共 50 条
  • [1] A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027
    Yuji Minegishi
    Ou Yamaguchi
    Shunichi Sugawara
    Shoichi Kuyama
    Satoshi Watanabe
    Kazuhiro Usui
    Masahide Mori
    Osamu Hataji
    Toshihiro Nukiwa
    Satoshi Morita
    Kunihiko Kobayashi
    Akihiko Gemma
    BMC Cancer, 21
  • [2] A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027
    Minegishi, Yuji
    Yamaguchi, Ou
    Sugawara, Shunichi
    Kuyama, Shoichi
    Watanabe, Satoshi
    Usui, Kazuhiro
    Mori, Masahide
    Hataji, Osamu
    Nukiwa, Toshihiro
    Morita, Satoshi
    Kobayashi, Kunihiko
    Gemma, Akihiko
    BMC CANCER, 2021, 21 (01)
  • [3] A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations
    Tanaka, Hisashi
    Taima, Kageaki
    Tanaka, Yoshihito
    Itoga, Masamichi
    Ishioka, Yoshiko
    Nakagawa, Hideyuki
    Baba, Keisuke
    Hasegawa, Yukihiro
    Takanashi, Shingo
    Tasaka, Sadatomo
    MEDICAL ONCOLOGY, 2018, 35 (03)
  • [4] A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations
    Hisashi Tanaka
    Kageaki Taima
    Yoshihito Tanaka
    Masamichi Itoga
    Yoshiko Ishioka
    Hideyuki Nakagawa
    Keisuke Baba
    Yukihiro Hasegawa
    Shingo Takanashi
    Sadatomo Tasaka
    Medical Oncology, 2018, 35
  • [5] AFATINIB FOR THE TREATMENT OF PATIENTS WITH EGFR-POSITIVE NON-SMALL CELL LUNG CANCER
    Bowles, D. W.
    Weickhardt, A.
    Jimeno, A.
    DRUGS OF TODAY, 2013, 49 (09) : 523 - 535
  • [6] First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations
    Tomohito Kuwako
    Hisao Imai
    Tomomi Masuda
    Yosuke Miura
    Kaori Seki
    Reiko Yoshino
    Kyoichi Kaira
    Mitsuyoshi Utsugi
    Kimihiro Shimizu
    Noriaki Sunaga
    Yoshio Tomizawa
    Shinichi Ishihara
    Takao Ishizuka
    Akira Mogi
    Takeshi Hisada
    Koichi Minato
    Atsushi Takise
    Ryusei Saito
    Masanobu Yamada
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 761 - 769
  • [7] A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632
    Noro, Rintaro
    Igawa, Satoshi
    Bessho, Akihiro
    Hirose, Takashi
    Shimokawa, Tsuneo
    Nakashima, Masanao
    Minato, Koichi
    Seki, Nobuhiko
    Tokito, Takaaki
    Harada, Toshiyuki
    Sasada, Shinji
    Miyamoto, Shingo
    Tanaka, Yosuke
    Furuya, Naoki
    Kaburagi, Takayuki
    Hayashi, Hideki
    Iihara, Hirotoshi
    Okamoto, Hiroaki
    Kubota, Kaoru
    LUNG CANCER, 2021, 161 : 49 - 54
  • [8] Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
    Kazuo Tamura
    Toshihiro Nukiwa
    Akihiko Gemma
    Nobuyuki Yamamoto
    Masaya Mizushima
    Kaori Ochai
    Rie Ikeda
    Hisaya Azuma
    Yoichi Nakanishi
    International Journal of Clinical Oncology, 2019, 24 : 917 - 926
  • [9] Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
    Tamura, Kazuo
    Nukiwa, Toshihiro
    Gemma, Akihiko
    Yamamoto, Nobuyuki
    Mizushima, Masaya
    Ochai, Kaori
    Ikeda, Rie
    Azuma, Hisaya
    Nakanishi, Yoichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (08) : 917 - 926
  • [10] A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer
    van Veggel, Bianca A. M. H.
    van der Wekken, Anthonie J.
    Paats, Marthe S.
    Hendriks, Lizza E. L.
    Hashemi, Sayed M. S.
    Daletzakis, Antonios
    van den Broek, Daan
    Bosch, Linda J. W.
    Monkhorst, Kim
    Smit, Egbert F.
    de Langen, Adrianus J.
    CANCER, 2024, 130 (05) : 683 - 691
12345